• 1
    Gines P, Berl T, Bernardi M, et al. Hyponatremia in cirrhosis: from pathogenesis to treatment. Hepatology 1998; 28: 85164.
  • 2
    Gunnet JW, Demarest KT. Aquaretic Efficacy of RWJ-351647 after Repeated Administration in the Rat (DD02023). EDMS-USRA-8079485:3.0; RWJPRI drug discovery report (23 September 2002), Johnson & Johnson Pharmaceutical Research & Development, High Wycombe, UK.
  • 3
    Gunnet JW, Hageman W, Demarest KT. Aquaretic Efficacy of RWJ-351647 in Cynomolgus Monkeys (DD02024). EDMS-USRA-8079493; RWJPRI drug discovery report (9 December 2002), Johnson & Johnson Pharmaceutical Research & Development, High Wycombe, UK.
  • 4
    Frame V, Gibson D, Harris R, et al. A Randomized, Double-Blind, Placebo-Controlled, 14-Day Multiple Dose Study of the Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Effects of Oral RWJ-351647 in Healthy Male Volunteers (Protocol 351647-CDE-102). Document ID No: EDMS-USRA-9020154; J&JPRD clinical study report (30 April 2004), Johnson & Johnson Pharmaceutical Research & Development, High Wycombe, UK.
  • 5
    Guyader D, Patat A, Ellis-Grosse EJ, Orczyk GP. Pharmacodynamic effects of a nonpeptide antidiuretic hormone V2 antagonist in cirrhotic patients with ascites. Hepatology 2002; 36: 1197205.
  • 6
    Gines P, Jimenez W. Aquaretic agents: a new potential treatment of dilutional hyponatremia in cirrhosis. J Hepatol 1996; 24: 50612.
  • 7
    Inoue T, Ohnishi A, Matsuo A, et al. Therapeutic and diagnostic potential of a vasopressin-2 antagonist for impaired water handling in cirrhosis. Clin Pharmacol Ther 1998; 63: 56170.
  • 8
    Yamamura Y, Ogawa H, Yamashita H, et al. Characterization of a novel aquaretic agent, OPC-31260, as an orally effective, nonpeptide vasopressin V2 receptor antagonist. Br J Pharmacol 1992; 105: 78791.
  • 9
    Ohnishi A, Orita Y, Okahara R, et al. Potent aquaretic agent. A novel nonpeptide selective vasopressin 2 antagonist (OPC-31260) in men. J Clin Invest 1993; 92: 26539.
  • 10
    Fernandez-Varo G, Ros J, Cejudo-Martin P, et al. Effect of the V1a/V2-AVP receptor antagonist, Conivaptan, on renal water metabolism and systemic hemodynamics in rats with cirrhosis and ascites. J Hepatol 2003; 38: 75561.
  • 11
    Udelson JE, Smith WB, Hendrix GH, et al. Acute hemodynamic effects of conivaptan, a dual V(1A) and V(2) vasopressin receptor antagonist, in patients with advanced heart failure. Circulation 2001; 104: 241723.
  • 12
    Wong F, Blei AT, Blendis LM, Thuluvath PJ. A vasopressin receptor antagonist (VPA-985) improves serum sodium concentration in patients with hyponatremia: a multicenter, randomized, placebo-controlled trial. Hepatology 2003; 37: 18291.
  • 13
    Gerbes AL, Gulberg V, Gines P, et al. Therapy of hyponatremia in cirrhosis with a vasopressin receptor antagonist: a randomized double-blind multicenter trial. Gastroenterology 2003; 124: 9339.
  • 14
    Gheorghiade M, Niazi I, Ouyang J, et al. Vasopressin V2-receptor blockade with tolvaptan in patients with chronic heart failure: results from a double-blind, randomized trial. Circulation 2003; 107: 26906.
  • 15
    Gheorghiade M, Gattis WA, O'Connor CM, et al., Acute and Chronic Therapeutic Impact of a Vasopressin Antagonist in Congestive Heart Failure (ACTIV in CHF) Investigators. Effects of tolvaptan, a vasopressin antagonist, in patients hospitalized with worsening heart failure: a randomized controlled trial. JAMA 2004; 291: 196371.